Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study October 30, 2026 Read More »
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse October 22, 2026 Read More »
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum June 5, 2026 Read More »
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger April 21, 2026 Read More »
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses March 27, 2026 Read More »
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan March 26, 2026 Read More »
